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INTRODUCTION
Acute lymphoblastic leukemia (ALL) represents almost one
third of pediatric cancer diagnoses, making it the most common
malignancy in childhood [1]. ALL is most commonly of the B cell
lineage and its incidence peaks between ages 2 and 4 years.
B-precursor ALL (B-ALL)—despite the high rate of cure—remains
one of the leading causes of cancer-related death among children
[2]. Somatically acquired genetic aberrations in ALL lymphoblasts
are prognostic and can guide risk-directed therapy. The extent
to which germline variation contributes to ALL susceptibility,
however, is less clear and is subject of current research.
Direct evidence for a genetic predisposition to ALL is provided
by the high risk associated with Bloom syndrome, neurofibromato-
sis, ataxia teleangiectasia, and Down’s syndrome. The heritable
basis of susceptibility to ALL is further supported by recent
candidate gene (CGAS) and genome-wide association studies
(GWAS), suggesting that co-inheritance of multiple germline
variants may contribute to disease risk. Five GWAS have been
performed so far with populations between 50/50 and 3,275/4,817
ALL cases/healthy control individuals [3–7]. These studies
identified several risk loci with allelic odds ratios (OR) of the
disease-related allele between 1.34 and 9.99.
Enciso-Mora et al. [8] calculated that 25% of the total variation
in B-ALL risk is accounted for by common genetic variation. On
the other hand, previous GWAS-identified loci (IKZF1, CDKN2A,
ARID5B, and CEBPE) explain only 8% of this total. The data
provide the rationale for continued investigation of additional
susceptibility loci that were likely missed by previous GWAS.
AlthoughGWAS represent a powerful approach to the identification
of disease loci, the P-value requirement for defining a significant
association, in turn, may increase the probability of missing a true
association [9].
In the present study we, therefore, have chosen a CGAS
approach which was based on the assumption that known risk loci
for many types of cancer are a priori also potential risk loci for
B-ALL. Single nucleotide polymorphisms (SNPs) were selected
from the SNP500Cancer database, which is biased towards SNPs
that liewithin or are situated close to cancer “candidate” genes [10].
We genotyped 1,421 polymorphisms in 407 candidate genes using
the Illumina Cancer SNP Panel BeadChip assay (Illumina, San
Diego, CA). We investigated an unselected population of B-ALL
patients recruited in a single center irrespective of ethnic
background to identify risk loci independent of ethnicity.
METHODS
Clinical Samples
Patients diagnosed with acute lymphoblastic leukemia (ALL)
who were diagnosed and treated at the Children’s Hospital of
Background. A genetic predisposition to acute lymphoblastic
leukemia (ALL) in childhood is well established. Currently known risk
loci, however, explain only one third of the estimated total risk
related to common genetic variations. Procedure. We genotyped
1,421 polymorphisms in 407 candidate genes from the
SNP500Cancer database (National Cancer Institute) using the
Illumina Cancer SNP Panel. We investigated 78 cases (aged 0–19
years at diagnosis, and mixed ethnic background) of childhood B-
precursor ALL and compared genotype data with those of 1,417
HapMap controls. To account for the ethnic diversity of the study
population, structured association by genetically matching cases and
controls using identity-by-state similarity was used. Case-control
association analyses were performed using Cochran–Mantel–
Haenszel tests, adjusted for the population substructure. Results.
Common variations rs6966 (30 UTR of PPP1R13L, chr 19q13.32,
P¼4.55109) and rs414580 (intron 2 of MSR1, chr 8p22,
P¼6.09108) were significantly associated with ALL. These
SNPs remained significant after adjustment for multiple testing.
The SNP rs6966 tags a haplotype block which includes SNPs in
PPP1R13L and ERCC2 genes, which are related to DNA repair and
cell survival. rs6966 and rs414580 conferred allelic odds ratios of
3.74 (95% confidence interval [CI] 2.31–6.04) and 3.93 (95% CI
2.31–6.69), respectively. Conclusions. These findings reveal two
independent novel susceptibility loci for childhood ALL. Pediatr
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Michigan, Detroit, USA between 1993 and 2007 were screened for
inclusion. Genomic DNA was extracted from discarded blood
samples obtained for routine clinical hematology studies. All
samples were anonymized prior to testing. The research protocol
was approved by the Human Investigation Committee of Wayne
State University School of Medicine.
Seventy-eight children with B-precursor ALL who had finished
the treatment protocols and had remission blood or bone marrow
samples available were recruited. Patient characteristics are
summarized in Table I. Genomic DNA was extracted from the
samples using Qiagen genomic DNA extraction kits (QIAGEN,
Inc., Valencia, CA). Quantity and quality of the gDNA was
evaluated by using Molecular Probes PicoGreen Assay (Molecular
Probes, Eugene, OR).
SNP Selection, Genotyping, and Quality Control
Genotyping was performed using the Illumina Cancer SNP
Panel on the GoldenGate Assay system according to the
manufacturer’s instructions (Illumina). The Cancer Panel contains
1,421 SNPs in 407 hypothesized cancer-related genes from the
SNP500Cancer database (Cancer Genome Anatomy Project,
National Cancer Institute). SNPs were chosen from public
databases and reports, and the choice of genes includeds a bias
towards non-synonymous and promoter SNPs in genes that have
been implicated in one or more cancers (PMID 16381944,
14681474). The Illumina Cancer SNP Panel includes genes of
several cancer-related pathways, such as oncogenesis, tumor
suppression, oxidative and hypoxic stress, detoxification, DNA
mismatch repair, regulation of transcription and cell cycle,
metabolism and immune regulation, and different carriers and
transport proteins. Genes and pathways covered by the Cancer SNP
Panel are shown in the Supplemental Table I. In the Cancer SNP
Panel, more than three SNP assays were selected, on average, for
each gene represented. It was not the primary intention of this study
to replicate previous GWAS or CGAS results but to find novel
candidates. In fact, there is only a small overlap between SNPs and
genes covered by the Illumina Cancer SNP Panel and loci identified
in previous association studies. For example, 56% of the genes and
22% of the SNPs identified in the meta-analysis of CGAS by
Vijayakrishnan et al. [11] were included in the Cancer SNP Panel.
Mathematical clustering and automatic genotype calling
algorithms, implemented in the GenomeStudio software (Illumina),
was used to analyze the raw intensity data. To assess the genotype
quality, we manually inspected the cluster plots and corrected
genotype assignment where automatic genotype calling failed.
SNPs that could not be clustered or were non-polymorphic were
excluded from further analyses. The average genotyping call rate
for all samples was 98.8%. If the call rate for any sample was below
95%, the sample was excluded from further analysis. Other quality
criteria included minor allele frequency (MAF) 0.01 and P-value
for the Hardy–Weinberg equilibrium test >0.01. Forty-two SNPs
were removed during quality control, leaving 1,387 SNPs for
analysis.
To exclude genotyping artifacts, candidate SNPs were geno-
typed with an independent technology. We used the TaqMan
platform and predesigned SNP Genotyping Assays Reagents
(Applied Biosystems, Foster City, CA) to re-genotype rs6966
(C_2615637_10) and rs414580 (C_1865305_10) as described
before [12].
We used the HapMap population (N¼ 1,417) as a control.
Genotype data were retrieved from the publicly accessible HapMap
database (1,417 samples; HapMap Genome Browser release #28,
The International Hapmap Project, available at http://hapmap.ncbi.
nlm.nih.gov/; genotype data were available for 1,169 SNPs
included in the Illumina Cancer SNP Panel) and from Illumina
(subset of 269 CEU, CHB/JPT, and YRI samples from the HapMap
population, genotype data were available for all 1,421 SNPs).
Statistical Analysis
To adjust for inflation due to population stratification, structured
association by genetically matching cases and controls using
identity-by-state (IBS) similarity as implemented in PLINK [13]
was used. Complete linkage agglomerative clustering was
performed, based on pairwise IBS distance, with some modifica-
tions to the clustering process: restrictions based on a significance
test for whether two individuals belong to the same population (i.e.,
do not merge clusters that contain significantly different individua-
ls), a phenotype criterion (i.e., all clusters must contain at least one
ALL case and one control) and cluster size restrictions (i.e., such
that, with a cluster size of two, the subsequent association test
would implicitly match every case with its nearest control, as long
as the case and control do not show evidence of belonging to
different populations). Based on the matrix of IBS pairwise
distances, multi-dimensional scaling (MDS) components were
obtained using the MDS-plot option in PLINK. MDS plots,
generated with R, visualize substructure and provide quantitative
indices of population genetic variation. Stratified case-control
association analyses were performed using Cochran–Mantel–
Haenszel tests, adjusted for the population substructure by inclusion
of the IBS cluster information. All the statistical results are reported
without correction, unless indicated otherwise. Control of the error
rate under multiple testing was done using false discovery rate
(FDR) adjustment as implemented in PLINK. After exclusion of
TABLE I. Patient and Biological Characteristics
Cases (n¼ 78)
Sex
Male 44 (56.4%)
Female 34 (43.6%)
Race
African Americans 13 (16.7%)
Asian Americans & Pacific Islander Americans 4 (5.1%)
Indian Americans 3 (3.8%)
Caucasians 58 (74.4%)
Age at diagnosis
<10 years 62 (79.5%)
10 years 16 (20.5%)
Immunophenotype
B-precursor ALL 74 (94.8%)
Mixed lineage ALL 2 (2.6%)
No information 2 (2.6%)
TEL/AML1
Positive 16 (20.5%)
Negative or no information 62 (79.5%)
MLL/AF4
Positive 1 (1.3%)
Negative or no information 77 (98.7%)
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some SNPs after quality control and based on the LD structure
of cases and controls, we calculated the effective number of
independent tests in our analysis at 1,379. Power analysis was done
with PS Power and Sample Size v3.0 [14].
RESULTS
Before comparing allele frequencies between cases and
controls, we considered biases due to nonrandom distribution of
technical artifacts or to population differences between case and
control data, which would result in a non-null distribution of test
statistics with excess false-positive associations. Therefore, we
assessed the median distribution of test statistics with the genomic-
control parameter lGC and examined the tail of the distribution
of association statistics in a comparison of observed and expected
P-values (Q-Q plot; Fig. 1). After adjustment for inflation due to
population stratification, lGC was markedly reduced, falling from
5.86 to 1.29. The MDS plot shows clustering of cases within the
major control populations (Fig. 2).
To exclude genotyping artifacts, candidate SNPs were geno-
typed with an independent technology. The concordance of
genotype calls was greater than 98%, indicating that the extreme
tail of low P-values was not substantially contaminated by
genotyping artifacts.
Our analysis revealed a significant association of the (noncod-
ing) haplotype-tagging SNPs rs6966 (NM_001142502.1: c.486A
>T, chr 19q13.3) in the protein phosphatase 1 regulatory subunit
13 like (PPP1R13L) gene (P¼ 4.55 109) and rs414580
(NM_002445.3: c.103þ 93A>T, chr 8p22) in the macrophage
scavenger receptor 1 (MSR1) gene (P¼ 6.09 108) with ALL
(Fig. 3). For both SNPs, the respective T alleles were associated
with increased ALL risk. A third SNP, rs11762213 (NM_000245.2:
c.144G>A, chr 7q31) in the MET proto-oncogene (MET), showed
only borderline significance (P¼ 2.97 102 after correction for
multiple testing). The SNPs rs6966 in PPP1R13L, rs414580 in
MSR1, and rs11762213 inMET conferred allelic odds ratios of 3.74
(95% CI 2.31–6.04), 3.93 (95% CI 2.31–6.69), and 7.57 (95% CI
2.52–22.78), respectively. MAFs in cases/controls of the total
population were 0.77/0.46 (rs414580), 0.77/0.47 (rs6966), and
0.23/0.03 (rs11762213). MAFs in cases/controls in the Caucasian
subpopulations (N¼ 64/463) were 0.77/0.40 (rs414580), 0.85/0.35
(rs6966), and 0.23/0.04 (rs11762213).
Based on HapMap data, haplotype block organization in the
rs6966 and rs414580 regions was investigated using criteria based
on solid spine of linkage disequilibrium method (D0> 0.8) with
Haploview software. Figure 4 shows LD maps in the HapMap
European (CEU/TSI) population (LD plots for Asian and African
populations are shown in Supplemental Figs. 1 and 2). The
SNP rs6966 was in LD with SNPs in PPP1R13L as well as
excision repair cross-complementing rodent repair deficiency-
complementation group 2 (ERCC2).
In addition to identifying new loci associated with ALL risk,
we sought to replicate previous positive associations. Six SNPs
previously linked in genome-wide or candidate gene association
studies with ALL risk were included in the Illumina SNP Cancer
Panel, namelyCDKN2A rs3731217 (P¼ 0.1022; OR 0.54), EPHX1
rs1051740 (P¼ 0.3648; OR 0.77),MTHFR rs1801133 (P¼ 0.7829;
OR 0.93), MTR rs1805087 (P¼ 0.1390; OR 0.62), SLC19A1
rs1051266 (P¼ 0.7984; OR 0.93), and XRCC1 rs25487
(P¼ 0.3248; OR 1.30) [11,15–18]. The respective genotype data
were thus available for analysis. None of these SNPs were
significantly (after correction for multiple testing) associated with
ALL in our study. It is important to note that, because our study
was powered to detect an OR >2.3 (power of >80% to detect
associations with OR >2.3 at a nominal significance level of
3.5 105 and a minor allele frequency of 0.3), we cannot exclude
that these SNPs are significantly associated with ALL at a lower
OR level.
Fig. 1. Q–Q plot for the association of 1,387 tested SNPs and the ALL
risk after controlling the study population (1,417 controls and 78 ALL
cases) for confounding by ethnicity (identity-by-state clustering
approach). The Q–Q plot allows assessment of the number and
magnitude of observed associations between genotyped SNPs and
ALL, compared to the association statistics expected under the null
hypothesis of no association.
Fig. 2. Multidimensional scaling plot of the identity by state matrix.
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DISCUSSION
This is the first study evaluating an association of SNPs in
“cancer genes” from the SNP500 database with childhood ALL.
Similar analyses using the Illumina Cancer SNP Panel were
successfully applied previously to identify risk loci for example for
colorectal or prostate cancer [19,20].
The SNPs identified in our analysis, rs6966, rs414580, and
rs11762213, have not been associated previously with childhood
ALL in GWAS or CGAS. The tag SNP rs6966, located on
chromosome 19q13.3, is in LD with polymorphisms in ERCC2 and
PPP1R13L, genes related to DNA repair and cell survival.
PPP1R13L induces apoptosis by blocking NFkB or inhibits
apoptosis by blocking P53 [21,22]. By either mechanism, the
gene could influence the survival of precancerous lesions, and it has
been speculated that PPP1R13L participates in the tumorigenesis
process [22–24]. A first link between PPP1R13L and ALL was
provided by the observation that PPP1R13L gene expression
was significantly higher in cells of acute leukemia than that in cells
from healthy donors or acute leukemia patients in complete
remission [25].
The 50 ! 30 helicase proteinERCC2 (also known as XPD) has an
important role in the nucleotide excision repair (NER) pathway [26].
. The NER pathway plays a major role in cell protection against
genotoxic damage by repairing DNA lesions such as those induced
byUVirradiation or chemical carcinogens [27]. Inherited variations
in DNA-repair efficiency have been implicated in the predisposition
to de novo and therapy-related AML [28,29]. Moreover, Hernan-
dez-Boluda et al. [29] identified rs13181 in ERCC2 as an
independent risk factor for leukemic transformation in primary
myelofibrosis, even though their finding is not without controver-
sy [30,31]. Several reports linked polymorphisms in the ERCC2
gene with enhanced risk of childhood ALL [32,33], although
negative results were also reported [34,35]. A meta-analysis was
able to confirm an association of the ERCC2 locus with ALL [26].
We identified rs6966 as a potential susceptibility locus, but it
remains a challenge to pinpoint the causal variant, which may be
located in PPP1R13L or ERCC2. Both genes have been linked with
tumorigenesis or leukemic transformation and thus may play a role
in the development of ALL.
Fig. 4. LD maps of the regions adjacent to rs6966 in PPP1R13L and
rs414580 in MSR1 in European (CEU/TSI) populations. The SNPs
rs6966 and rs414580 are highlighted in green. Shading reflects
differences in pairwise LD (white r2¼ low LD; red r2¼ near-perfect
LD). Numbers in squires are estimates of pairwise coefficients (D0),
expressed in percentages. Unreported values reflect D0 of 1.0 (100%).
Fig. 3. Manhattan plot showing the association of SNPs with ALL. The P-values (log10P) plotted against their respective positions on each
chromosome. Each chromosome is depicted in a different color.log10 (UNADJ), –log10P value of Cochran–Mantel–Haenszel test unadjusted for
multiple testing.
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The other tag SNP identified in our study, rs414580, is located in
the 8p22 region in the MSR1 gene [36]. Genetic polymorphisms in
MSR1 have been shown to be related to prostate cancer risk,
although the underlying mechanism is unclear [37]. In a mouse
chronic myeloid leukemia (CML) model, Chen et al. [38]
demonstrated that MSR1 suppresses leukemia stem cells and
CMLdevelopment. Interestingly, the ALL susceptibility lociMSR1
(this study) andCEBPE (previous studies [3,39],) both play a role in
normal macrophage function [40,41].
The third significantly associated SNP in our analysis was
rs11762213 in MET, although only at borderline significance.
Germline mutations located in the MET proto-oncogene, which
lead to a constitutive activation of the MET protein, have been
linked with the development of hereditary papillary renal
carcinoma [42]. Moreover, the germline genetic polymorphism
rs11762213 has been associated with the risk of recurrence in
patients with localized renal-cell carcinoma [43]. This SNP,
however, has not been associated previously with childhood ALL.
Six SNPs previously linked with susceptibility to childhood
ALL were included in our SNP panel. Previous studies showed that
the effect size of these SNPs was small and associations became
obvious, in some cases, only after combining results from different
studies in meta-analyses (OR 1.1–1.4) [11,15–18]. Our study was
powered to detect an OR >2.3, which explains the lack of
association of these SNPs in our study.
Limitations of our study include the small sample size. Our
study had statistical power of>80% to detect only associations with
OR >2.3 at a nominal significance level of 3.5 105 (this
significance threshold is required when accounting for multiple
comparisons) and aminor allele frequency of 0.3. Nevertheless, this
is the first study that systematically screened tagging and several
coding variants in established cancer risk genes in a comprehensive
manner to identify ALL susceptibility loci. The study was restricted
to precursor B-ALL patients. Although the study design precludes
any statements on the relevance of the identified risk loci for
patients with the T-cell immunophenotype, restriction to B-ALL
reduced the heterogeneity of the study population and thus
improved the power. Patients were not selected according to their
ethnic background, which on the one hand necessitated statistical
adjustments but on the other hand enabled identification of
susceptibility loci not restricted to only one major ethnic group.
In conclusion, by screening 1,421 SNPs in “cancer genes” we
identified two novel loci, namely ERCC2/PPP1R13L and MSR1,
which are potentially associated with susceptibility to childhood
ALL. Confirmation of the association is required in an independent
study population with greater statistical power. Rapid advances in
the development of sequencing technologies will enable cost-
effective screening of several thousand clinically relevant SNPs
in childhood ALL in the near future. As a proof-of-concept,
Wesolowska et al. [9] applied a novel multiplexing method with
custom-designed baits to screen 25,000 SNPs in childhood ALL.
ACKNOWLEDGMENTS
The present work was performed as part of the doctoral thesis
of S.O. This work is supported by the German Kind-Philipp-
Stiftung and the Georgie Ginopolis Chair endowment award to
Dr. Ravindranath and a grant from Leukemia Research Life, Inc.;
the authors also wish to acknowledge initial encouragement for the
project by Dr. Richard Everson.
REFERENCES
1. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute
leukemias: An update. J Clin Oncol 2011;29:551–565.
2. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest
2012;122:3407–3415.
3. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated
with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009;41:1006–1010.
4. Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute
lymphoblastic leukemia. Nat Genet 2009;41:1001–1005.
5. Han S, Lee KM, Park SK, et al. Genome-wide association study of childhood acute lymphoblastic
leukemia in Korea. Leukemia Res 2010;34:1271–1274.
6. Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 influences childhood acute
lymphoblastic leukemia risk. Nat Genet 2010;42:492–494.
7. Ellinghaus E, StanullaM, Richter G, et al. Identification of germline susceptibility loci in ETV6-RUNX1-
rearranged childhood acute lymphoblastic leukemia. Leukemia 2012;26:902–909.
8. Enciso-Mora V, Hosking FJ, Sheridan E, et al. Common genetic variation contributes significantly to the
risk of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 2012;26:2212–2215.
9. Wesolowska A, DalgaardMD, Borst L, et al. Cost-effective multiplexing before capture allows screening of
25,000 clinically relevant SNPs in childhood acute lymphoblastic leukemia. Leukemia 2011;25:1001–1006.
10. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: A public resource for sequence validation, assay
development, and frequency analysis for genetic variation in candidate genes. Nucl Acid Res 2006;34:
D617–D621.
11. Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute
lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 2010;95:1405–1414.
12. Trenk D, Hochholzer W, FrommMF, et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects
of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011;
4:429–436.
13. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and
population-based linkage analyses. Am J Hum Genet 2007;81:559–575.
14. Dupont WD, Plummer WD, Jr. Power and sample size calculations. A review and computer program.
Controlled Clin Trials 1990;11:116–128.
15. Wang L, Yin F, Xu X, et al. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms
and risk of childhood acute lymphoblastic leukemia: A meta-analysis. PLoS ONE 2012;7:e34897.
16. Urayama KY, Chokkalingam AP, Manabe A, et al. Current evidence for an inherited genetic basis of
childhood acute lymphoblastic leukemia. Int J Hematol 2013;97:3–19.
17. Wang H, Wang J, Zhao L, et al. Methylenetetrahydrofolate reductase polymorphisms and risk of acute
lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies. BMCMed Genet
2012;13:77.
18. de Jonge R, Tissing WJ, Hooijberg JH, et al. Polymorphisms in folate-related genes and risk of pediatric
acute lymphoblastic leukemia. Blood 2009;113:2284–2289.
19. Chen J, Pande M, Huang YJ, et al. Cell cycle-related genes as modifiers of age of onset of colorectal
cancer in Lynch syndrome: A large-scale study in non-Hispanic white patients. Carcinogenesis 2013;
34:299–306.
20. Barwick BG, Abramovitz M, Kodani M, et al. Prostate cancer genes associated with TMPRSS2-ERG
gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 2010;102:570–576.
21. Gillotin S, iASPP, a potential drug target in cancer therapy. Leukemia Res 2009;33:1175–1177.
22. Laska MJ, Vogel UB, Jensen UB, et al. p53 and PPP1R13L (alias iASPP or RAI) form a feedback loop to
regulate genotoxic stress responses. Biochim Biophys Acta 2010;1800:1231–1240.
23. Yin J, Guo L, Wang C, et al. Effects of PPP1R13L and CD3EAP variants on lung cancer susceptibility
among nonsmoking Chinese women. Gene 2013;524:228–231.
24. Pinto EM, Musolino NR, Cescato VA, et al. iASPP: A novel protein involved in pituitary tumorigenesis?
Front Horm Res 2010;38:70–76.
25. Zhang X, Wang M, Zhou C, et al. The expression of iASPP in acute leukemias. Leukemia Res
2005;29:179–183.
26. Wang F, Chang D, Hu FL, et al. DNA repair gene XPD polymorphisms and cancer risk: A meta-analysis
based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev 2008;17:507–517.
27. Popp HD, Bohlander SK. Genetic instability in inherited and sporadic leukemias. Genes Chromosome
Cancer 2010;49:1071–1081.
28. Allan JM, Smith AG,Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of
acute myeloid leukemia following chemotherapy. Blood 2004;104:3872–3877.
29. Hernandez-Boluda JC, Pereira A, Cervantes F, et al. A polymorphism in the XPD gene predisposes to
leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and
polycythemia vera. Blood 2012;119:5221–5228.
30. Susini MC, Guglielmelli P, Spolverini A, et al. The ERCC2 Gln/Gln polymorphism at codon 751 is not
associated with leukaemic transformation in primary myelofibrosis. Br J Haematol 2013;162:424–427.
31. Poletto V, Villani L, Catarsi P, et al. No association between theXPDLys751Gln (rs13181) polymorphism
and disease phenotype or leukemic transformation in primary myelofibrosis. Haematologica 2013;98:
e83–84.
32. Ganster C, Neesen J, Zehetmayer S, et al. DNA repair polymorphisms associated with cytogenetic
subgroups in B-cell chronic lymphocytic leukemia. Genes Chromosome Cancer 2009;48:760–767.
33. Chokkalingam AP, Bartley K, Wiemels JL, et al. Haplotypes of DNA repair and cell cycle control genes,
X-ray exposure, and risk of childhood acute lymphoblastic leukemia. Cancer Cause Control
2011;22:1721–1730.
34. Batar B, Guven M, Baris S, et al. DNA repair gene XPD and XRCC1 polymorphisms and the risk of
childhood acute lymphoblastic leukemia. Leukemia Res 2009;33:759–763.
35. Pakakasama S, Sirirat T, Kanchanachumpol S, et al. Genetic polymorphisms and haplotypes of DNA
repair genes in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007;48:16–20.
36. Alvarez-Cubero MJ, Saiz M, Martinez-Gonzalez LJ, et al. Genetic analysis of the principal genes related
to prostate cancer: A review. Urol Oncol 2013;31:1419–1429.
37. Sun J, Hsu FC, Turner AR, et al. Meta-analysis of association of rare mutations and common sequence
variants in the MSR1 gene and prostate cancer risk. Prostate 2006;66:728–737.
38. Chen Y, Sullivan C, Peng C, et al. A tumor suppressor function of theMsr1 gene in leukemia stem cells of
chronic myeloid leukemia. Blood 2011;118:390–400.
39. Xu H, YangW, Perez-Andreu V, et al. Novel susceptibility variants at 10p12.31–12.2 for childhood acute
lymphoblastic leukemia in ethnically diverse populations. J Natl Canc Inst 2013;105:733–742.
40. Seimon TA, Obstfeld A, Moore KJ, et al. Combinatorial pattern recognition receptor signaling alters the
balance of life and death in macrophages. Proc Natl Acad Sci U S A 2006;103:19794–19799.
41. Tanaka T, Akira S, Yoshida K, et al. Targeted disruption of the NF-IL6 gene discloses its essential role in
bacteria killing and tumor cytotoxicity by macrophages. Cell 1995;80:353–361.
42. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the
MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68–73.
43. Schutz FA, Pomerantz MM, Gray KP, et al. Single nucleotide polymorphisms and risk of recurrence of
renal-cell carcinoma: A cohort study. Lancet Oncol 2013;14:81–87.
Pediatr Blood Cancer DOI 10.1002/pbc
Risk Loci in ALL 1415
